AstraZeneca gets regulator’s nod to market cancer drug Imfinzi for additional indication
The receipt of this permission paves way for the marketing of Durvalumab solution for infusion 120 mg/2.4 mL and 500 mg/10 mL (Imfinzi) in India
The receipt of this permission paves way for the marketing of Durvalumab solution for infusion 120 mg/2.4 mL and 500 mg/10 mL (Imfinzi) in India
What's Your Reaction?
